



NEWS RELEASE

# Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

2024-10-09

Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis on the management of SE

RADNOR, Pa.--(BUSINESS WIRE)-- **Marinus Pharmaceuticals**, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22 nd Annual Meeting, being held October 14-17 in San Diego, California.

Presentation details are as follows:

## Podium Presentation Details:

Thursday, October 17, 2024, 9:35-9:55 a.m. PT

- Title: Efficacy and Safety of Intravenous Ganaxolone for Treatment of Refractory Status Epilepticus: Results from the Phase 3, Double-Blind, Randomized, Placebo-Controlled RAISE Trial
- Presenting Author : Brandon Foreman, M.D., M.S., FACNS, FNCS, Associate Professor of Neurology & Rehabilitation Medicine and Neurosurgery at the University of Cincinnati and Associate Director for Neurocritical Care Research
- Session: Late-Breaking Science Oral Platform

## Poster Presentation Details:

Wednesday, October 16, 2024, 2:45-3:45 p.m. PT

- Title: High Rate of Interhospital Transfers in Status Epilepticus: Challenges in Management of Care
- Presenting Author : Henrikas Vaitkevicius, M.D., VP, Clinical Development, Marinus Pharmaceuticals
- Session: Poster Session Day 2

## About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company's product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit

**[www.marinuspharma.com](http://www.marinuspharma.com)** and follow us on **Facebook**, **LinkedIn** and **X**.

### Investors

Sonya Weigle

Chief People and Investor Relations Officer

Marinus Pharmaceuticals, Inc.

**[sweigle@marinuspharma.com](mailto:sweigle@marinuspharma.com)**

### Media

Molly Cameron

Director, Corporate Communications & Investor Relations

Marinus Pharmaceuticals, Inc.

**[mcameron@marinuspharma.com](mailto:mcameron@marinuspharma.com)**

Source: Marinus Pharmaceuticals